Prelude Capital Management, LLC Alpine Immune Sciences, Inc. Transaction History
Prelude Capital Management, LLC
- $1.85 Billion
- Q1 2024
A detailed history of Prelude Capital Management, LLC transactions in Alpine Immune Sciences, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 27,100 shares of ALPN stock, worth $0. This represents 0.06% of its overall portfolio holdings.
Number of Shares
27,100
Previous 41,500
34.7%
Holding current value
$0
Previous $790,000
35.95%
% of portfolio
0.06%
Previous 0.05%
Shares
2 transactions
Others Institutions Holding ALPN
# of Institutions
185Shares Held
62MCall Options Held
158KPut Options Held
199K-
Decheng Capital LLC Menlo Park, CA8.32MShares$044.22% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.78MShares$02.76% of portfolio
-
Black Rock Inc. New York, NY3.58MShares$00.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.13MShares$06.52% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.08MShares$00.01% of portfolio
About ALPINE IMMUNE SCIENCES, INC.
- Ticker ALPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 44,006,700
- Description
- Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...